Cyramza for Non-Small Cell Lung Cancer - Details

Détails

Generic Name:
Ramucirumab
Fabricant:
Eli Lilly Canada Inc.
Brand Name:
Cyramza
Gamme de produits:
Examen en vue du remboursement
Tumour Type:
Lung
Indications:
Non-Small Cell Lung Cancer
Funding Request:
For the treatment of patients with advanced or metastatic non-small cell lung cancer who progressed on or after platinum-based chemotherapy in combination with docetaxel
Review Status:
Dossier fermé – Non présenté
Pre Noc Submission:
Yes
Date NOC Issued:
Sponsor:
Eli Lilly Canada Inc.
Clarification:
The submitter notified pCODR that they will not be filing the submission.
Clarification:
The submitter notified pCODR that they were unable to submit by their original target date and an updated target submission date has been provided.

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.